PHARMACEUTICAL HUB SWITZERLAND ESPACE MITTELLANDBASSIN LÉMANIQUE
TABLE OF CONTENTS
Preface 4 Pharmaceutical Industry in Switzerland Swiss Pharmaceutical Cluster Espace Mittelland-Bassin Lémanique Innovation Capacity Inward Investment Factors
6 8 10 18 26
Company Profiles 32 Glossary 40
ESPACE MITTELL AND-BASSIN LÉMANIQUE
3
PREFACE
Councillor Philippe Leuba, Head of the Department of Economic Affairs, Innovation and Sport in the Canton of Vaud
Within just a few decades, Western Switzerland has become a leading life sciences hub and a genuine “Health Valley”. Almost 1,000 industry-related companies are located in the region including start-ups, SMEs, multinationals, 20 research institutes and universities. A total of 25,000 people are employed in the life sciences sector, making it one of the three largest European centres in this domain, alongside Cambridge and Oxford in England. Several pharmaceutical production companies have located in the region between Lake Geneva and Lake Neuchâtel. Merck’s state-of-the-art, recently expanded biotech production facility in Aubonne is a case in point. This is Merck’s main production site, providing biopharmaceutical medicines for patients worldwide. The life sciences sector is booming. Strong partnerships make this a leading region in the research fields of neurosciences, cancer, immunology, nutrition and cardiovascular diseases. Bioinformatics, medical imaging and robotic surgery are other rapidly evolving areas. A centre for cancer research will be inaugurated near the Lausanne University Hospital (CHUV), bringing together 300 researchers and doctors. This project illustrates the sector’s rise and vitality in the region.
4
PHARMACEUTICAL HUB SWITZERL AND
Numerous orders are generated for regional companies when a pharmaceutical company opens a new site or expands an existing one. The production facilities must be built, equipped and maintained. This benefits local industry, which can multitask. In addition to the 43,000 or so jobs generated directly in the pharmaceutical industry, around 138,000 jobs are created in other companies (including maintenance technicians and computer scientists) across Switzerland. In addition to jobs in the pharmaceutical industry, medical research and production are synonymous with hope and cure, bringing happiness to thousands of sick people. Various factors are responsible for the region’s appeal. Tax is one such factor, if not the main one. The availability of highly qualified workers and the proximity to major universities such as the Swiss Federal Institute of Technology in Lausanne (EPFL) or the University of Geneva, are crucial factors. Last but not least, our region’s greatest strength lies in its ability to create a mutually beneficial network for all stakeholders. In short, the unique depth and breadth of competence in biosciences and medical technologies is at the centre of a diversified economic structure, both in terms of company size (start-ups, SMEs, multinationals) and activities (R&D, production, headquarters). The growth prospects for the Bassin Lémanique Area remain promising.
ESPACE MITTELL AND-BASSIN LÉMANIQUE
5
PHARMACEUTICAL INDUSTRY IN SWITZERLAND
7.2%
AVERAGE ANNUAL GROWTH RATE OF REAL GROSS VALUE ADDED (2006–2016)
4.3× MORE PRODUCTIVE THAN OVERALL ECONOMY (2016)
SWISS FRANCS NOMINAL GROSS VALUE ADDED (2016)
45,500 EMPLOYEES (2016)
Study on behalf of Interpharma Further information on the economic importance of the Swiss pharmaceutical industry is provided in our publication, entitled “The Importance of the Pharmaceutical Industry for Switzerland”. This is available on our website at Publikationen/Pharmastandort. 6
PHARMACEUTICAL HUB SWITZERL AND
Source: BAK Economics, Polynomics, FSO, 2017
28.9 BN.
The pharmaceutical industry significantly impacts the Swiss economy both directly and indirectly. The direct economic importance can be measured, for example, by the value of exports, number of employees or gross value added (GVA). The latter is calculated by deducting the value of intermediate goods and services from the goods produced (production value). In 2016, the nominal GVA of the pharmaceutical industry amounted to 28.9 billion Swiss francs – an approximate fourfold increase compared to 20 years earlier. With an average annual growth rate of real GVA of 7.2 per cent, the pharmaceutical industry has impacted considerably on the growth of the Swiss economy in recent years. The indirect effects of the pharmaceutical industry can be measured in addition to its direct effects. Approximately 138,000 additional (full-time) jobs have been generated through cross-industry collaboration with other companies, taking pharmaceutical industry intermediate goods and services into account. Similarly, the employee demand for consumer goods and services together with the tax revenue from the pharmaceutical companies have an indirect effect on the overall economy. The direct and indirect GVA amount to approximately 49.6 billion Swiss francs. Furthermore, pharmaceutical companies in Switzerland invest heavily in research and development (R&D). In 2012, the share of private-sector investment in R&D accounted for around 2 per cent of the national gross domestic product (GDP). This high rate of investment highlights the importance of the Swiss research hub. In addition, the sector is making a significant contribution to ensuring that Switzerland is also perceived as an innovation driver internationally, leading the European and global innovation rankings. ESPACE MITTELL AND-BASSIN LÉMANIQUE
7
Around
88%
OF THE SWISS PHARMACEUTICAL INDUSTRY NOMINAL GROSS VALUE ADDED was achieved in the Basel Region, Espace MittellandBassin Lémanique and Zurich-Zug-Lucerne clusters in 2016.
n Basel Region n Espace Mittelland-
Bassin Lémanique n Zurich-Zug-Lucerne
n Schaffhausen n Ticino n Valais
8
PHARMACEUTICAL HUB SWITZERL AND
Source: BAK Economics, 2018
SWISS PHARMACEUTICAL CLUSTER
Basel Region The Basel Region Pharmaceutical Cluster comprising the cantons of Basel-Stadt, Basel-Land and Jura together with Fricktal and Dorneck-Thierstein, is of major international importance. International companies such as Actelion, Bayer, Boehringer Ingelheim, Novartis and Roche are located in this area. Espace Mittelland-Bassin Lémanique The cantons of Bern, Fribourg, Neuchâtel and Solothurn are located in the Espace Mittelland Area whilst the Geneva and Vaud cantons are located in the Bassin Lémanique Area. Together they form the Espace Mittelland-Bassin Lémanique cluster, which is home to the Swiss branches of Biogen, Celgene, Eli Lilly, GlaxoSmithKline, Merck, Sanofi, UCB and Vifor Pharma. Zurich-Zug-Lucerne The Zurich-Zug-Lucerne cluster has grown into an attractive location for international life sciences companies. It is home to the following companies: AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, Gilead, Janssen, Lundbeck, Merck, MSD (Merck Sharp & Dohme), Novartis, Pfizer, Roche, Shire, Takeda and Vifor Pharma. Schaffhausen / Ticino / Valais There are also three smaller pharmaceutical clusters in Switzerland: In Schaffhausen, the pharmaceutical industry plays an important role for the local economy and is based primarily on the activities of Cilag. In the Ticino cluster, the pharmaceutical industry has grown historically and now includes several medium-sized companies. Valais is extremely important as the area accommodates suppliers who produce chemical inputs for pharmaceutical production. ESPACE MITTELL AND-BASSIN LÉMANIQUE
9
ESPACE MITTELLANDBASSIN LÉMANIQUE THE PHARMACEUTICAL INDUSTRY IN THE ESPACE MITTELLAND-BASSIN LÉMANIQUE CLUSTER
7.0%
AVERAGE ANNUAL GROWTH RATE OF REAL GROSS VALUE ADDED (2006–2016)
51
PATENT APPLICATIONS in 2013 (per million inhabitants)
3.8 BN. SWISS FRANCS NOMINAL GROSS VALUE ADDED
7,600 EMPLOYEES in 2016
10
PHARMACEUTICAL HUB SWITZERL AND
Source: OECD, BAK Economics, 2018
(2016)
The manufacture of medical devices is amalgamated with the life sciences industry. This includes the pharmaceutical industry, medical technology (electric and orthopaedic) as well as biotechnology, all of which are heavily engaged in research and development. In recent decades, the two areas, Espace Mittelland and Bassin Lémanique, have developed into an internationally recognised hub for companies in the life sciences sector. The cluster is characterised by the pool of renowned research and training institutions such as the Swiss Federal Institute of Technology in Lausanne (EPFL). Other factors such as the availability of skilled employees have led various companies in the sector to settle in this area. For instance, the biotechnology company Biogen opted to construct a state-of-the-art biopharmaceutical production plant in Luterbach in the canton of Solothurn. Companies settling in the Espace Mittelland-Bassin Lémanique cluster have led to a constant increase in the number of employees.
ESPACE MITTELL AND-BASSIN LÉMANIQUE
11
ESPACE MITTELLAND-BASSIN LÉMANIQUE
EMPLOYMENT IN THE LIFE SCIENCES SECTOR Share of overall employment (as %), 2016 Øresund
2.47.6
Switzerland
1.5
Boston
1.3
Espace Mittelland
1.2
Bassin Lémanique
0.9
SF Bay Area
0.9
Singapore New York
0.5
Paris
0.5 0.2
London 0%
1%
2%
3%
Particularly large workforce in medical technology As one of the major employers in the area, the life sciences industry in the Espace Mittelland-Bassin Lémanique cluster has a workforce of approximately 20,100 – which accounts for around 1.1 per cent of overall cluster employment. This corresponds to approximately one quarter of all individuals employed in the Swiss life sciences industry. Approximately 12,700 and 7,400 people are employed in the life sciences sector in Espace Mittelland and Bassin Lémanique, respectively.
12
PHARMACEUTICAL HUB SWITZERL AND
Source: BAK Economics, 2018
0.9 0.7
Munich
EMPLOYMENT IN THE LIFE SCIENCES SUB-SECTORS Share relative to total number of employees (as %), 2016 59
Espace Mittelland
34
33
Bassin Lémanique
47
Bern
49
34
Solothurn
22
85
Vaud
49 20%
2 45
40%
60%
1 19
44
13 0%
5 52
32
Neuchâtel
7
56
47
Geneva
8 46
39
Fribourg
7
59
80%
5 100%
Pharmaceutical industry Medical technology Biotechnology Possible rounding differences
Taking the life sciences sub-sectors into account, the pharmaceutical industry is the biggest employer in Switzerland in terms of national average. The picture in the Espace Mittelland-Bassin Lémanique Area is different. A large part of the workforce in this area is employed by the medical technology industry. The area therefore contributes to Switzerland’s leading role in the medical technology sector.
ESPACE MITTELL AND-BASSIN LÉMANIQUE
13
Source: BAK Economics, 2018
Switzerland
ESPACE MITTELLAND-BASSIN LÉMANIQUE
VALUE ADDED IN THE LIFE SCIENCES SECTOR Value added relative to regional total value added (as %), 2016 Øresund
8.9
Switzerland
5.6
Singapore
3.9
Espace Mittelland
3.3
Bassin Lémanique
2.5
SF Bay Area
2.1
Boston 1.1
Munich
1.0
Paris
0.9
London
0.4 0%
2%
4%
6%
8%
10%
The pharmaceutical industry is the strongest sector in terms of value added In the Espace Mittelland-Bassin Lémanique cluster, life sciences value added accounted for approximately 2.9 per cent of overall cluster value added in 2016. Considering individual areas, the share in the Espace Mittelland area with 3.3 per cent is slightly higher than the 2.5 per cent recorded in the Bassin Lémanique Area. The cluster therefore outstrips other international life sciences hubs such as the San Francisco Bay Area or Paris. Breaking down the individual figures, the pharmaceutical industry with 3.8 billion Swiss francs in 2016 accounted for approximately 1.7 per cent of the cluster’s overall value added, surpassing the 0.9 per cent value added of the medical technology sector.
14
PHARMACEUTICAL HUB SWITZERL AND
Source: BAK Economics, 2018
2.0
New York
GROWTH RATE OF REAL GROSS VALUE ADDED AND EMPLOYMENT Average annual growth rate in life sciences (as %), 2006–2016 Singapore Øresund Bassin Lémanique Switzerland Espace Mittelland Munich Boston SF Bay Area New York London –8% –6% –4% –2%
0%
2%
4%
6%
8% 10% 12%
Real gross value added Employment
Positive value added and employment growth Between 2006 and 2016, the average growth rate in terms of real gross value added in the life sciences sector in the Espace Mittelland-Bassin Lémanique cluster was approximately 5.1 per cent. Particularly intense growth was noted essentially in the Bassin Lémanique Area with an average annual real GVA growth rate of 7.6 per cent. Cluster employment in life sciences increased by 2.8 per cent over the same period. Breaking down individual figures, the Bassin Lémanique Area witnessed stronger employment growth than the Espace Mittelland Area. Compared to international life sciences hubs, an above-average level of growth has been recorded in the Bassin Lémanique life sciences sector.
ESPACE MITTELL AND-BASSIN LÉMANIQUE
15
Source: BAK Economics, 2018
Paris
ESPACE MITTELLAND-BASSIN LÉMANIQUE
PRODUCTIVITY IN THE LIFE SCIENCES SECTOR Nominal labour and hourly productivity (in CHF, current prices and exchange rates), 2016 0
100,000
200,000
300,000
400,000
500,000
0
100
200
300
400
500
Switzerland SF Bay Area Øresund Bassin Lémanique Singapore New York London Boston Paris Munich
Nominal labour productivity (top axis) Nominal hourly productivity (below axis)
Pharmaceutical industry with high productivity In terms of productivity, the individual Espace Mittelland and Bassin Lémanique Areas certainly performed well compared to international life sciences hubs. In 2016, nominal labour productivity in the Espace Mittelland Area amounted to 299,000 Swiss francs compared to 354,000 Swiss francs per workplace in the Bassin Lémanique Area. The latter was therefore more productive.
16
PHARMACEUTICAL HUB SWITZERL AND
Source: BAK Economics, 2018
Espace Mittelland
Although the medical technology industry in the Espace Mittelland-Bassin Lémanique cluster has a stronger workforce than the pharmaceutical industry, value added is higher in the pharmaceutical sector. This can be attributed to the fact that the pharmaceutical industry is by far the most productive industry and therefore generates a higher valued added than other branches of industry but with the same number of employees. Thus, in 2016, the pharmaceutical industry in Bassin Lémanique generated 283 Swiss francs per working hour or around 520,000 Swiss francs per workplace. In the Espace Mittelland Area, 266 Swiss francs were generated per working hour and/or approximately 484,000 Swiss francs per workplace. Lower values were recorded in other sub-sectors.
“Hot on the heels of our firmly consolidated medtech sector, life sciences is rapidly gaining ground in the Southern Jura region. In 2019, the US biotechnology company Biogen will commission one of the world’s most modern biopharmaceutical production plants in the Solothurn Area. We are delighted that the canton of Solothurn put forward such a strong case in its bid to become the chosen location, highlighting its skilled workforce and excellent accessibility amongst other things. Fortunately, Biogen’s decision to settle here has been a driving force.” Government Councillor Brigit Wyss, Head of the Department of Economics, Canton of Solothurn
ESPACE MITTELL AND-BASSIN LÉMANIQUE
17
INNOVATION CAPACITY
18
PHARMACEUTICAL HUB SWITZERL AND
Companies must be able to make dynamic adjustments in order to survive in an ever-changing commercial climate. Innovation – the commercial implementation of new ideas and their impact on the business market – is one of the most important growth factors of a modern economy. For several years, Switzerland has been one of the world’s most innovative countries. Thanks to cutting-edge innovation, Switzerland is a strong competitor in the international stakes. Particularly in knowledge-intensive sectors, capacity for innovation is an important factor when facing location decisions. Companies in the life sciences sector are therefore also interested in locations with a high innovation potential. The framework conditions in the Espace Mittelland-Bassin Lémanique cluster that influence the area’s capacity for innovation are shown on the following pages. Research and development expenditure, patent density, the quality of regional universities and the level of education of the workforce are analysed for this purpose.
ESPACE MITTELL AND-BASSIN LÉMANIQUE
19
INNOVATION CAPACITY
RESEARCH AND DEVELOPMENT EXPENDITURE Share of GDP (as %), 2012 0.3
2.4
Denmark
2.0
0.1
1.0
Switzerland
2.1
0.0
0.8
Germany
2.0
France
1.8
UK
1.0
Spain Italy 0%
0.5
0.4 0.3 0.5
1.5
USA
0.7
0.2
0.2
0.1 0.4
0.7
0.2 0.4
0.7
0.2 0.4 1%
2%
3%
4%
Private sector Public sector Universities
Private sector invests heavily in research and development Intensive research and development will generate new knowledge which, in turn, leads to innovation. A great deal is invested into the research and development of new medicines in Switzerland. Consequently, the pharmaceutical industry contributes to Switzerland’s competitive edge and economic growth. In 2012, research and development expenditure in the private and public sectors coupled with universities accounted overall for approximately 2.9 per cent of the Swiss GDP. Switzerland therefore stands out from the crowd thanks to its intensive research activities and has consolidated its position on the international stage. Investments in R&D are mostly in the private sector: The share of private-sector-financed R&D expenditure account ed for approximately 2 per cent of the GDP in 2012. 20
PHARMACEUTICAL HUB SWITZERL AND
Source: OECD, BAK Economics, 2017
Finland
PATENT APPLICATIONS Number of patent applications per million inhabitants, 2013 Boston
110
SF Bay Area
85
46
Øresund
92
32
Bassin Lémanique
52
47 24
Switzerland Munich
50
44 33
80
39
16 12
Espace Mittelland
4 32 4
New York
17 15 7
Paris
12 11 10
Singapore
7 11 11
London
7 8 4 0
100
200
300
Pharmaceutical industry Medical technology Biotechnology
Catch-up potential in patent applications The number of patent applications provides an insight into the innovative capacity of a region. It allows research productivity to be assessed and the commercial value of knowledge to be measured on a worldwide scale. A total of 202 patents were filed in the life sciences sector in the Espace Mittelland-Bassin Lémanique cluster in 2013. Around 4 pharmaceutical patent applications per million inhabitants were filed in the Espace Mittelland Area and approximately 47 per million inhabitants in the Bassin Lémanique Area. The two areas are thus below and above average, respectively. This puts both areas well behind the Boston cluster which filed more than 100 pharmaceutical patent applications per million inhabitants, and is thus the leading hub.
ESPACE MITTELL AND-BASSIN LÉMANIQUE
21
Source: OECD, BAK Economics, 2017
10 24 13
INNOVATION CAPACITY
QUALITY OF THE UNIVERSITIES Index 100 = ø of the benchmark areas (Western Europe and USA between 2010 and 2014), 2016 Boston Bassin Lémanique
114
SF Bay Area
112
Singapore
111
Øresund
107
New York
106
Switzerland
103
London
102
Paris
100
Munich
100
Espace Mittelland
100 0
40
80
120
160
High quality of regional universities High-quality academic research institutes attract specialists and high-level scientists from all over the world, thus benefitting other areas in addition to research. The quality of local universities is therefore an important location factor, which is particularly relevant for research-intense sectors such as the pharmaceutical industry. The Espace Mittelland-Bassin Lémanique cluster has excellent universities. In addition to the prestigious Swiss Federal Institute of Technology in Lausanne (EPFL), the universities in the canton of Geneva rank among the highest-quality universities in the world. Universities in the
22
PHARMACEUTICAL HUB SWITZERL AND
Source: CWTS Leiden Ranking, BAK Economics, 2017
155
QUALITY OF THE UNIVERSITIES IN THE LIFE SCIENCES SECTOR Index 100 = ø of the benchmark areas (Western Europe and USA between 2010 and 2014), 2016 Boston
131
Øresund
113
Bassin Lémanique SF Bay Area
109
Switzerland
105
Singapore
105
New York
102
Espace Mittelland
101
London
99
Paris
99
Munich
99 0
35
70
105
140
Bassin Lémanique Area scored 114 points and are therefore way out in front. Compared with universities in the field of life sciences, the institutions in the Bassin Lémanique area perform very well. Espace Mittelland universities rank lower, but still compare relatively well with other life sciences universities.
BAK Quality of Universities Index The BAK Quality of Universities Index is based on the CWTS Ranking of Leiden and assesses the quality of universities in a given area. It is measured by the number of publications generated by a university in the fields of biomedical and health sciences and their citation frequency.
ESPACE MITTELL AND-BASSIN LÉMANIQUE
23
Source: CWTS Leiden Ranking, BAK Economics, 2017
110
INNOVATION CAPACITY
LEVEL OF EDUCATION Share of gainfully employed (as %), 2014 41
Finland
41
Switzerland
38
Spain
37
France
36
Denmark
34
Austria
42
45
19 22
54
15
60
19 0%
15 39
44
27
Italy
13
48 23
32
Germany
17
46
13
47 20%
40%
34 60%
80%
100%
Tertiary Secondary Primary Possible rounding differences
Highly qualified workforce Employees’ qualifications are an important indicator of the competitive edge and innovative capacity of an economy. For sectors with a high research and development activity, such as the pharmaceutical industry, professionals with tertiary education are particularly important. In 2014, the proportion of tertiary-educated employees in Switzerland accounted for more than one third (38%) of all those in gainful employment, compared to just under one quarter in 2000. Employees with secondary education still represent the largest share with approximately 48 per cent. Compared to other European countries, Switzerland has a high level of education.
24
PHARMACEUTICAL HUB SWITZERL AND
Source: OECD, BAK Economics, 2017
UK
“The canton of Solothurn has a particularly high density of medtech companies. Over 10 per cent of all Switzerland’s medtech jobs are located in the canton of Solothurn. Home to Biogen, the canton of Solothurn presents itself as an internationally acclaimed hub for life sciences companies. Approximately 12,700 people work in the life sciences industry in the Espace Mittelland.” Daniel Probst, Director of the Solothurn Chamber of Commerce
ESPACE MITTELL AND-BASSIN LÉMANIQUE
25
INWARD INVESTMENT FACTORS
26
PHARMACEUTICAL HUB SWITZERL AND
In addition to in-house variables, inward investment factors are also important for companies in order to optimise their economic activity. In the light of globalisation, inward investment factors are of increasing commercial importance. The inward investment factor discussion can be viewed from two perspectives: Whereas hard factors such as taxation and regulation are mostly relevant for companies, other factors including the level of education and quality of life are more important for employees. An improvement in regional location quality is therefore important in order to remain attractive for companies already settled or interested in settling in a given area as well as for highly qualified employees. Various indicators such as taxation, accessibility and regulation are considered on the following pages to evaluate the location quality of the Espace Mittelland-Bassin LĂŠmanique cluster.
ESPACE MITTELL AND-BASSIN LÉMANIQUE
27
INWARD INVESTMENT FACTORS
MARKET REGULATION
4.0
IT FR
3.0
FR
IT 2.0 DE 1.0 0.0 0.0
UK 0.5
1.0
FI DK
FI CH
UK
CH US
US 1.5
ES
DK
ES
DE
2.0
2.5
3.0
3.5
PRODUCT MARKET REGULATION INDEX
2015 1995
Economy-friendly regulation State regulations can lead to high administrative costs or preclude market access. However, at the same time, regulations can also promote competition and pro-business structures. The intensity of (labour and product) market regulation therefore has a significant impact on the attractiveness of a location. Generally, it should be noted that all comparative countries were regulated to less of an extent in 2015 compared to 1995. The international comparison of the way labour and product markets are regulated shows that Switzerland had a moderate level of regulation in 2015. Whilst the Anglo-Saxon countries in particular have an even more liberal market structure, regulation in Spain, Italy and especially France is essentially higher than in Switzerland.
28
PHARMACEUTICAL HUB SWITZERL AND
Source: OECD, Cato Institute, BAK Economics, 2017
LABOUR MARKET REGULATION INDEX
Product and labour market regulation index (0 = very liberal; 6 = strictly regulated), 1995 and 2015
BAK TAXATION INDEX Taxation of companies and highly qualified workforce, ø 1995–2017 New York Boston Munich
30%
London Bassin Lémanique
20% 10%
SF Bay Area Paris Øresund
Espace Mittelland
Singapore
0% 0%
10%
20%
30%
40%
50%
60%
TAXATION OF HIGHLY QUALIFIED WORKFORCE
Competitive taxation system Taxation is one of the most important factors in international competition for business locations. This is because the tax system of an area is extremely important for both companies and employees alike. Switzerland and its areas have a competitive tax system. In the Espace Mittelland-Bassin Lémanique cluster, taxation for companies and highly qualified employees tends to be lower on international comparison. The area’s business locations are therefore extremely attractive in terms of tax and surpass other international life sciences locations in this regard.
Measurement of taxation (Taxation Index) Company taxation including all indirect company taxes and/or for a highly qualified employee earning 100,000 euros after tax. ESPACE MITTELL AND-BASSIN LÉMANIQUE
29
Source: ZEW, BAK Economics, 2017
TAXATION OF COMPANIES
40%
INWARD INVESTMENT FACTORS
DOING BUSINESS INDEX Maximum: Index 100, 2010 and 2015 Denmark UK Finland Germany Switzerland France Spain Italy 0
15
30
45
60
75
90
2010 2015
Competitive conditions In 2015, Switzerland ranked 26th1 in the Doing Business Index and was therefore in the middle tier of high-earning OECD countries. In terms of a European comparison, Switzerland ranked behind the Nordic countries and in front of the Southern European countries.
Doing Business Index The index ranks economies according to their ease of doing business. The higher the ranking, the more business-friendly the regulatory conditions are in terms of starting and operating a local firm.
1
Source: The World Bank, 2016
30
PHARMACEUTICAL HUB SWITZERL AND
Source: World Bank, BAK Economics, 2017
USA
GLOBAL ACCESSIBILITY London
120
Paris
119
Øresund
112
New York
112
Munich
111
Boston
109
Switzerland
109
Bassin Lémanique
108
Espace Mittelland
107
SF Bay Area
94 0
20
40
60
80
100
120
140
Good international accessibility Accessibility of production locations and markets plays a major role when choosing a business location. As various corporate processes often take place in different locations in the course of globalisation, international networking is particularly important. The Espace Mittelland-Bassin Lémanique cluster is less accessible than comparable international life sciences locations, but still has above-average performance. In this respect, the Bassin Lémanique Area can benefit from its proximity to Geneva airport whilst Zurich airport is more significant for the Espace Mittelland Area.
Measurement of accessibility (Accessibility Index) Indexed value that quantifies the global accessibility of a region. It reflects the outbound accessibility from a region to locations in the rest of the world. ESPACE MITTELL AND-BASSIN LÉMANIQUE
31
Source: TransSol, BAK Economics, 2017
Index (100 = ø of all areas inspected 2002), 2016
COMPANY PROFILES
Biogen A pioneering biotechnology company, Biogen currently has the leading portfolio of medicines to treat multiple sclerosis (MS), the first authorised treatment for the management of spinal muscle atrophy and is spearheading research into new drugs for neurological and neurodegenerative diseases such as Alzheimer’s disease. The company also produces and markets biosimilars. Biogen was founded in Geneva in 1978. The company’s international head office, the Biosimilars business unit and the Swiss subsidiary are located in Zug, where Biogen has a 400-strong workforce. In Luterbach in the canton of Solothurn, Biogen is currently investing one billion Swiss francs in the construction of a new, state-of-theart biopharmaceutical production facility. Production is scheduled to start in 2019 and up to 400 new posts will be created for highly qualified staff. www.biogen.ch www.biogen-solothurn.ch
32
PHARMACEUTICAL HUB SWITZERL AND
Celgene Celgene is a global biopharmaceutical company that is engaged in the therapeutic areas of haematology, oncology and inflammatory and immunological diseases. Intensive research, development and ongoing provision of innovations in the fields of chronic and rare diseases form the basis of its efforts to offer patients the best-possible treatments. More than 30 per cent of annual sales at Celgene are therefore reinvested in research and development. The aim of Celgene is to help prolong the life of patients and achieve a sustainable improvement in their quality of life. The company currently employs around 6,000 people worldwide. Switzerland is a very important centre for the company with its international headquarters and production in Boudry NE (800 employees), another production site in Zofingen AG (20 employees) and the Swiss subsidiary Celgene GmbH in Zurich (60 employees). www.celgene.com
ESPACE MITTELL AND-BASSIN LÉMANIQUE
33
COMPANY PROFILES
Eli Lilly Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. From the development of insulin to the manufacturing of the polio vaccine to the discovery of medicines that treat mental illness, we have been pioneers behind breakthroughs against some of humanity’s most devastating diseases. We currently have the richest mid-to-late-stage pipeline in our history, representing a variety of therapeutic areas including cancer, diabetes, neuroscience and autoimmunity. Lilly employs 41,000 people worldwide and has been present in Geneva since 1925, where 150 of its employees work. Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. www.lilly.ch
34
PHARMACEUTICAL HUB SWITZERL AND
GlaxoSmithKline (GSK) GSK has set itself the ambitious and inspirational task of improving the quality of life of people by enabling them to enjoy a more active, longer and healthier life (do more, feel better, live longer). As a research-based company, GSK discovers and develops innovative products mainly in the areas of pharmaceuticals, vaccines and consumer healthcare. GSK is thus a leading company in the management of respiratory diseases, infectious diseases and HIV. GSK is represented in more than 150 countries, has a network of 87 factories and major research centres in the USA, UK, Spain, Belgium and China. In Switzerland, GSK is based in MĂźnchenbuchsee BE and Rotkreuz ZG and is one of the most important pharmaceutical companies in the country with around 180 employees. In Nyon VD, GSK also has an international site for consumer healthcare with global functions and a production plant with around 1,000 employees. www.glaxosmithkline.ch
ESPACE MITTELL AND-BASSIN LÉMANIQUE
35
COMPANY PROFILES
Merck Merck KGaA with headquarters in Darmstadt, Germany, is a global pharmaceutical and chemical company with more than 50,000 employees in 66 countries. Healthcare is the largest division of Merck and is committed to the improvement of health and the development of new treatments. It focuses on highly specialised therapeutic areas, such as cancer, multiple sclerosis and infertility. Merck helps people who want to start a family, improves the quality of life for patients and helps to prolong life. In Switzerland, the company employs more than 2,000 people at sites in Aubonne VD, Coinsins VD, Corsier-sur-Vevey VD, Altdorf UR, Schaffhausen SH, Zug ZG, Buchs SG and Therwil BL. Aubonne’s recently extended state-of-the-art biotech manufacturing facility is the premier production site for biopharmaceutical medicines for patients all around the world. www.merckgroup.com
36
PHARMACEUTICAL HUB SWITZERL AND
Sanofi Sanofi is a world-leading healthcare company whose Swiss subsidiary employs around 150 people at four sites in Vernier, Basel, Frauenfeld and Baar. The company is mainly active in the following therapeutic areas: diabetes, central nervous system disorders, cardiovascular diseases and oncology, rare diseases and immunology. Its original prescription medicines are supplemented with generic products from Helvepharm, as well as a range of over-the-counter medicines. For many years Sanofi has played an active part in the debate on the development of the Swiss healthcare system. The annual forumsantĂŠ meetings, for example, which have been held now for 15 years, facilitate the exchange of pioneering ideas, many of which have been put into practice. www.sanofi.ch
ESPACE MITTELL AND-BASSIN LÉMANIQUE
37
COMPANY PROFILES
UCB UCB is one of the leading biopharmacy companies specialising in the treatment areas of immunology and neurology. UCB headquarters are located in Brussels (Belgium). The company employs more than 7,700 employees in over 40 countries, including a qualified workforce of approximately 470 in the Swiss city of Bulle (Greyerzerland). In response to the growing demand for biotech medicines for inflammatory diseases such as rheumatoid arthritis, certain forms of ankylosing spondylitis and Crohn’s disease, a new biotechnology production plant was opened in October 2014. www.ucb.com www.ucbsuisse.ch
38
PHARMACEUTICAL HUB SWITZERL AND
Vifor Pharma / Vifor SA The Swiss pharmaceutical company Vifor Pharma is one of the world’s leading companies in the research, development, production and marketing of pharmaceutical products for the treatment of iron deficiency disorders. Other core areas are nephrology and cardiorenal therapies. The company also offers a diversified portfolio of prescription medicines. The head office of Vifor Pharma Schweiz (Vifor SA) and one of the 4 production sites in Switzerland are based in Villars-sur-Glâne FR. The biotech company OM Pharma, which also belongs to the Vifor Pharma Group and specialises in immunology, is based in Meyrin GE. It produces over-the-counter medication for the treatment of various infectious diseases. Vifor Pharma has more than 1,100 employees in Switzerland including over 300 in Villars-sur-Glâne FR and approximately 200 in Meyrin GE. www.viforpharma.ch www.viforpharma.com
ESPACE MITTELL AND-BASSIN LÉMANIQUE
39
GLOSSARY
CHUV EPFL FSO GDP GVA ISIC OECD R&D
University Hospital in the Canton of Vaud Swiss Federal Institute of Technology in Lausanne Federal Statistical Office, Switzerland Gross Domestic Product Gross Value Added International Standard Industrial Classification of All Economic Activities Organisation for Economic Co-operation and Development Research and Development
Information on areas Boston Boston-Cambridge-Newton Munich Munich Region New York New York-Newark-Jersey City SF Bay Area San Francisco Bay Area Demarcation of the life sciences industry The definition of the life sciences industry used in this publication includes the following ISIC branches: Pharmaceutical Industry (21), Electronic Medical Technology (26.6), Orthopaedic Medical Technology (32.5) and Research and Development on Biotechnology (72.11).
40
PHARMACEUTICAL HUB SWITZERL AND
Publishing information Published by: Interpharma Association of research-based pharmaceutical companies in Switzerland Petersgraben 35 P.O. Box 4009 Basel Phone: 061 264 34 00 E-mail: info@interpharma.ch Website: www.interpharma.ch
The content of the publication can also be found on the Interpharma website at www.interpharma.ch. Graphics from the latest version may be downloaded for your free use provided the source is quoted. Design: Continue AG, Basel Print: Gremper AG, Pratteln Disponible en traduction française Deutsche Originalversion verfügbar © Interpharma, 2018 Photocopying permitted with acknowledgement of source
Interpharma Petersgraben 35, P.O. Box CH-4009 Basel Phone +41 (0)61 264 34 00 Fax +41 (0)61 264 34 01 info@interpharma.ch www.interpharma.ch